BeOne Medicines (ONC) Return on Equity (2016 - 2026)

BeOne Medicines (ONC) has 11 years of Return on Equity data on file, last reported at 0.0% in Q1 2026.

• Quarterly Return on Equity changed 0.0% year-over-year to 0.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.0% (changed 0.0% YoY) and the FY2025 annual result came in at 0.0%, changed 0.0% from the prior year.
• Return on Equity rose to 0.0% in Q1 2026 per ONC's latest filing, from 0.0% in the prior quarter.
• Across five years, Return on Equity topped out at 0.0% in Q1 2026 and bottomed at 0.0% in Q1 2023.
• The 5-year median for Return on Equity is 0.0% (2023), against an average of 0.0%.
• Peak annual rise in Return on Equity reached 0 bps in 2022, while the deepest fall reached 0 bps in 2022.
• Tracing ONC's Return on Equity over 5 years: stood at 0.0% in 2022, then jumped by 46 bps to 0.0% in 2023, then climbed by 21 bps to 0.0% in 2024, then soared by 135 bps to 0.0% in 2025, then surged by 66 bps to 0.0% in 2026.
• Per Business Quant, the three latest ONC Return on Equity figures stand at 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025).

Peer Comparison